Estrella Immunopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, · September 30, | ||||
| 2025 · 2024 | ||||
| Cash Flows from Operating Activities: | ||||
| Net loss | $(12,450,338) | $(7,797,339) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 470,614 | - | ||
| Change in fair value of derivative liabilities | 67,039 | - | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other receivable | 326,960 | (36,394) | ||
| Prepaid expenses - related party | - | (1,500,000) | ||
| Accounts payable - related party | 1,196 | (72,076) | ||
| Other payables and accrued liabilities | (126,145) | (81,598) | ||
| Accrued liability - related party | 10,106,666 | 2,744,000 | ||
| Franchise tax payable | (4,134) | (200) | ||
| Income tax payables | (50) | - | ||
| Net cash used in operating activities | (1,608,192) | (6,743,607) | ||
| Cash Flows from Financing Activities: | ||||
| Payments of transactions cost | (52,652) | - | ||
| Proceeds from issuance of common stock for PIPE investment | 2,400,000 | - | ||
| Purchase of treasury stock | (29,462) | (504,905) | ||
| Net cash provided by (used in) financing activities | 2,317,886 | (504,905) | ||
| Net Change in Cash | 709,694 | (7,248,512) | ||
| Cash at beginning of the period | 916,916 | 9,046,015 | ||
| Cash at end of the period | $1,626,610 | $1,797,503 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for income tax | $913 | $1,600 | ||
| Cash paid for interest | $ | - | $ | - |
| Supplemental Disclosure of Non-cash Financing Activities | ||||
| Recognition of derivative liabilities upon closing of the PIPE investment | $318,316 | $ | - | |
ESTRELLA IMMUNOPHARMA, INC
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.